Context decision
Choose one immune-cell problem and identify which external observations are directly relevant.
CRISPR / Project brief
Proposed project · No experimental result claimedImmune Discovery Partner Pilot
Choose the immune problem before choosing the platform.
Hypothesis to evaluate
A bounded question before a larger commitment.
A specialist-defined immune-cell question may support a controlled discovery partnership. T-cell tumor function and myeloid inflammatory polarization are separate candidate contexts.
Partner qualification dossier
Document actual expertise, material access, delivery context, assay competence, capacity and data rights.
Commissionable work package
An agreed scientific objective, functional readouts, independent units, safety questions and output-data requirements.
Capability needed
Immunology laboratory with relevant primary-cell expertise, quantitative analyst and a qualified discovery lead.
Reasons to revise or stop
Do not advance on proliferation alone or transpose a mouse target label directly onto its human counterpart. An unwanted inflammatory direction requires reassessment.
What must be agreed before work begins
An accountable scientific lead, authorized inputs, provider responsibilities, resources, relevant approvals, data handover, interpretation criteria and a written rights position. No named institution is presented as a contracted Karam partner.
The deliverable is not a guaranteed positive finding
A well-explained negative or inconclusive result can satisfy a properly scoped project. Acceptance should be based on the agreed work and evidence, not on a favorable claim.
Source trail
Scientific summaries are adapted from the supplied 15 October 2026 CRISPR Project Assessment. Source records show the original references and review access; this release is not a new systematic review.
C02 — Chen ACY, Ji KY, Yerinde C, et al. CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer. Cell. 29 July 2026.C08 — Jung H, Devant P, Ching C, et al. Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells. Nature Biotechnology. 17 August 2026.C09 — Jung H, Jeong B, Kim YW, et al. Precise genomic integration of large DNA fragments by donor-directed annealing using prime editing. Nature Biotechnology. 28 August 2026.Bring the capability that changes the project.
Scientific, analytical and laboratory partners can propose a specific contribution with evidence of their relevant work.